Trials / Completed
CompletedNCT00482976
Effect of LY333531 on Vascular and Neural Functions
The Effects of a Protein Kinase C Beta Inhibitor, LY333531, on Vascular and Neural Functions in Type 2 Diabetes Mellitus - Study B7A-MC-MBDM
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Chromaderm, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To determine if protein kinase C beta plays a significant role in vascular endothelial dysfunction, small fiber neural dysfunction, and oxidative stress associated with diabetes mellitus.
Detailed description
32mg Ruboxistaurin; 4 week cross-over treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruboxistaurin | |
| DRUG | Placebo |
Timeline
- Start date
- 2003-12-01
- Completion
- 2005-03-01
- First posted
- 2007-06-06
- Last updated
- 2016-07-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00482976. Inclusion in this directory is not an endorsement.